Home / Buy a Business / Home Health

Buy a Home Health Business in 2026: 8-15x by Sub-Vertical, PDGM, CHOW Timeline

Updated June 2026 · CT Acquisitions

Buying a home health business in 2026 is not one transaction type, it is three: Medicare-certified home health, non-medical home care, and Medicare hospice. Each has its own regulatory architecture, payor mix, multiple band, and buyer competitive set. The buyers winning deals right now (Kinderhook on Enhabit, General Atlantic on TEAM Services, Webster Equity holding Bristol Hospice, Pennant absorbing 54 Amedisys/Optum divestitures, BrightSpring picking up 107) all share one trait: they underwrote the PDGM 30-day episode case mix, the EVV vendor lock-in, and the CMS 855A CHOW timeline before they signed the LOI. This playbook covers what experienced buyers actually pay, what they diligence, how they structure the deal around CHOW lag and CON state friction, and where capital actually compounds across the three sub-verticals.

This guide is the buyer’s playbook for the home health, home care, and hospice categories. It covers how each sub-vertical is underwritten in 2026, which regulatory and operational signals separate a 7x deal from a 12x deal, what structures sellers actually accept when CHOW lag is on the table, and how to close acquisitions that compound past the first reimbursement cycle.

Why home health is the largest healthcare PE roll-up

Buying a home health business in 2026 sits at the intersection of the three biggest secular tailwinds in US healthcare services, and the deal volume reflects that.

First, demographics. The 65+ population crosses 62 million in 2026 and reaches 73 million by 2030. The 85+ cohort (the heaviest consumer of home health, home care, and hospice) grows roughly 4% annually through the decade. CMS projects home health spending to grow from $135 billion in 2023 to over $220 billion by 2031.

Second, payor preference for the home. Medicare Advantage penetration crossed 54% in 2025 and the plans are aggressively pushing post-acute care out of skilled nursing facilities and into the home. Hospital-at-home (CMS Acute Hospital Care at Home waiver) is now a permanent fixture after the March 2025 extension. Every dollar of inpatient avoidance flows through a home health agency, a home care provider, or a hospice.

Third, fragmentation. More than 11,400 Medicare-certified home health agencies, over 33,000 non-medical home care agencies, and roughly 5,800 hospice providers in the US. The top 10 home health players control under 30% of certified episodes. Every major PE platform in the space (Bain on Aveanna, CD&R and Humana on Gentiva, Webster Equity on Bristol Hospice, Levine Leichtman on Synergy HomeCare, Halifax Group on Comfort Keepers, Main Post on HomeWell, TowerBrook and Ascension on Compassus) is actively rolling up. The Amedisys/Optum closing in August 2025 alone produced 164 divestiture transactions that reshaped buyer rosters in 19 states.

For buyers, the combination is rare: a category with demographic certainty, payor pull, and enough independent supply to still matter at the $2–$50M EBITDA band. The difficulty is that home health is the most regulated subsector in healthcare services, and pricing already reflects strong buyer demand.

What buyers pay by sub-vertical in 2026

Unlike most home services categories, buying a home health business requires three separate valuation conversations because the three sub-verticals trade at materially different multiples. A $5M EBITDA Medicare-certified home health agency, a $5M EBITDA non-medical home care agency, and a $5M EBITDA hospice agency are three different assets with three different buyer pools and three different risk profiles.

Medicare-certified home health multiples

Non-medical home care multiples

Hospice multiples

The spread between bands is not random. It reflects six factors that every sophisticated home health buyer models explicitly:

• Payor mix. Traditional Medicare commands the highest multiples in home health and hospice; Medicare Advantage compresses margins (often 10–15% below FFS rates); Medicaid and MLTSS payor mixes price lower because state rate-setting risk is real.
• Case mix index. Under PDGM, the 432 case-mix groups drive 30-day episode payment. Agencies that have optimized OASIS coding and clinical grouping inside the regulatory envelope receive a multiple premium.
• HHVBP performance. The Home Health Value-Based Purchasing model went nationwide January 1 2025 with +/-5% adjustments. Top-quartile performers carry a 0.5–1.0x multiple premium; bottom-quartile performers carry a 1.0–1.5x discount.
• Caregiver retention. Annualized voluntary RN/LPN turnover under 25% in home health, under 50% for non-medical CNAs, is the benchmark. Above benchmark signals operational fragility.
• Referral concentration. Under 15% from any single hospital or physician group is platform-grade. Over 25% is often a deal breaker, particularly in hospice where Stark and AKS exposure compounds the risk.
• CON state footprint. Operating in a CON state (NC, GA, AL, MS, KY, WV, AR, IL, MI, NJ, NY, OH, PA, SC, TN, VA, WA) is a moat for the seller and a barrier for the buyer trying to grow organically.

The 2026 pricing reality

Pricing in home health has bifurcated. Platform-grade Medicare-certified agencies in the $5M+ EBITDA range routinely receive multiple LOIs at 9x–11x. The Enhabit go-private to Kinderhook Industries in May 2026 at $1.1B/$13.80 per share/10.2x EBITDA on $108M EBITDA and $1.06B revenue established the public market anchor. Hospice is hotter still: Bristol Hospice (a Webster Equity portfolio company) ran an active March 2026 auction on $140M EBITDA with $1B+ sponsor bids implied at the high end of the 12–15x band. Non-medical home care has not seen the same multiple expansion, but TEAM Services Group sold to General Atlantic in April 2026 for $3B at roughly 10x EBITDA, establishing the upper ceiling for the sub-vertical.

For independent and search-fund buyers competing with PE platforms, the implication is to either pursue a differentiated thesis (a CON state moat, an MLTSS contract you can defend, an underserved geography the platforms have skipped) or move to the $1–$3M EBITDA band where platform buyers are less active. In that range, multiples are still 5–7x and founders often prioritize continuity over absolute price.

The seven buyer archetypes in home health

Knowing which buyer you are (and which you are competing against) changes how you structure offers in home health, where buyer identity correlates tightly with payor sophistication and clinical model.

1. National PE platforms

Multi-state platform companies acquiring 5–30 add-ons over a 4–6 year hold. Kinderhook (now owning Enhabit), Webster Equity (Bristol Hospice), Bain Capital + JH Whitney (Aveanna), CD&R + Humana (Gentiva), Vistria + Nautic + Anthony Family Investment Partners (VitalCaring), TowerBrook + Ascension Health (Compassus), and Levine Leichtman (Synergy HomeCare since January 21 2025) sit at the top of this list. They pay the highest multiples (often 10x+ for $15M+ EBITDA targets) because they can apply debt across the platform and exit at a higher multiple than they acquired. Target profile: $5M+ EBITDA, multi-site, management depth, top-half HHVBP performance.

2. Strategic acquirers (large operators and health plans)

UnitedHealth/Optum (now owning Amedisys after the August 7 2025 close at $3.3B), Humana (CenterWell, acquired Intrepid USA Q3 2024), Addus HomeCare (acquired Gentiva personal care for $350M December 2 2024), Pennant Group (absorbed 54 Amedisys/Optum divestitures for $146.5M in 2025 as its largest transaction ever), and BrightSpring (absorbed 107 divestitures for $239M) lead the strategic buyer pool. They pay competitive multiples, particularly for targets that complete a geographic or clinical capability gap. Integration tends to be more thoughtful because they already operate the category.

3. Health system joint ventures

Compassus continues to set the JV pace: OhioHealth at Home JV September 2024, Providence JV October 2024 with Oregon approval May 18 2026, and the existing Ascension Health 50/50 ownership structure. These structures pay 8–11x for the home health asset plus a strategic premium for the JV optionality. Founders selling to a health-system JV typically keep more rollover equity (15–25%) than in a pure PE deal.

4. Independent sponsors and lower-middle-market PE

Deal-by-deal capital, usually focused on the $2–$10M EBITDA range that platforms skip. They compete on creative structuring (earnouts tied to HHVBP performance, rollover equity tied to CHOW completion, seller financing through the Medicare receivables ramp). Good fit for sellers in CON states with a defensible local share.

5. Search funds

Individual operators with institutional backing. Multiples: 5–7x SDE/EBITDA. Target profile: $1–$3M SDE in non-medical home care most commonly (the regulatory burden in Medicare-certified home health is hard for first-time operators to absorb). Good fit for founders who want a clean exit and a sponsor who will invest in caregiver retention.

6. Franchise consolidators

HomeWell Care Services (Main Post Partners since January 21 2026, its first PE sponsor, with 138 agencies across 37 states and approximately $100M system-wide revenue), Comfort Keepers (Halifax Group since September 2023, after Sodexo divested its entire Worldwide Home Care division), Synergy HomeCare (Levine Leichtman since January 21 2025, the third PE sponsor after NexPhase exited), Senior Helpers (Advocate Aurora Enterprises since April 1 2021), Honor with Home Instead (acquired August 2021, backed by Andreessen Horowitz, Baillie Gifford, and T. Rowe Price — not KKR), and U.S. Lawns adjacency franchise networks operate as both buyers (of franchise units) and competitors for non-franchise sellers. They typically pay 5–7x for franchise unit acquisitions and offer brand continuity.

7. Family offices and nonprofits

BAYADA Home Health Care converted to nonprofit 501(c)(3) status in January 2019 and is not for sale. Family offices increasingly compete for $5–$20M EBITDA hospice and home health assets where the long-hold thesis (10–25 years) and the absence of debt-pressure are attractive to founders prioritizing legacy.

Due diligence: the home-health-specific deep dive

Generic M&A due diligence is necessary but not close to sufficient when buying a home health business. The regulatory and operational layer is where every value-creation and value-destruction story actually lives. Here is what experienced home health buyers add to standard quality of earnings, legal, and insurance review.

PDGM case-mix audit (home health)

Pull 24 months of OASIS-E assessments and 30-day episode claims. Map every episode to its case-mix group (one of 432 under PDGM), its LUPA status, its clinical grouping, its functional impairment level, and its admission source. Identify whether the agency has drifted toward higher-paying case-mix groups in a pattern that would trigger a Targeted Probe and Educate review. Calculate the LUPA threshold compliance rate (target: under 8% of episodes triggering LUPA). The CY2025 base 30-day payment is $2,058.71 and the wage-index normalization matters. Any agency where the case-mix index has climbed more than 5% year-over-year without a clinical population shift is carrying audit risk.

Hospice cap and HOPE compliance audit

For hospice acquisitions: pull the trailing 36 months of per-beneficiary cap calculations. The FY2026 aggregate cap is $35,361.44 per beneficiary. Agencies that have run near or over cap in any of the trailing 36 months carry recoupment risk that should be reflected in indemnification holdbacks or escrow. Verify HOPE assessment compliance: HOPE replaced HIS October 1 2025 with a 4% APU penalty for non-compliance. Pull a sample of HOPE submissions and check completion rate, timing, and quality. Verify the four levels of care per-diem rates (RHC days 1-60 $231.16/day for FY2026, RHC days 61+, continuous home care, inpatient respite, general inpatient) align with the claimed payor mix and length of stay distribution.

HHVBP scorecard review

HHVBP went nationwide January 1 2025 with payment adjustments of +/-5%. Pull the agency’s Care Compare star rating, the HHVBP achievement and improvement scores, and the projected payment adjustment. Top-quartile performers receive +5% on the base PDGM payment; bottom-quartile performers lose 5%. The difference is roughly 10 points of margin on the same revenue base, which is why buyers underwrite this carefully.

EVV vendor and contract review

Electronic Visit Verification is federally mandated (personal care 2020, home health 2023). The dominant vendors are HHAeXchange, Sandata, and Tellus. Verify the agency’s EVV vendor, the state aggregator integration, the compliance rate (target: 95%+ of visits captured), and the contract assignability under a CHOW. A vendor lock-in with 18–36 months remaining and unfavorable assignment terms is a real diligence cost.

Caregiver workforce diligence

Build a caregiver-level retention and utilization dataset for the trailing 12 months. Key metrics: annualized voluntary turnover by role (RN, LPN, CNA, HHA, PT/OT/SLP), average tenure, hours per caregiver per week, callouts and no-show rate, and overtime burden. State minimum wage and wage parity overlays matter: California SB 525 ramps home health worker minimum to $25/hour, New York Wage Parity sits at approximately $23/hour in NYC, and the Washington Cares Fund 0.58% payroll tax produces benefit payments starting July 2026. Underwrite the next 24 months of caregiver cost inflation.

Stark, AKS, and physician relationship audit

Pull every contract with a referring physician, hospital, ALF, SNF, or any potential referral source. Verify fair market value substantiation, written agreements, and compliance with Stark and Anti-Kickback Statute requirements. Hospice deals carry particular scrutiny here because the Office of Inspector General has prioritized hospice fraud. Any contracted medical director compensation above the 75th percentile MGMA benchmark needs documented justification.

Survey and certification history

Pull every CMS survey, state survey, and accreditation (Joint Commission, CHAP, ACHC) report for the trailing 36 months. Condition-level deficiencies, immediate jeopardy findings, or plans of correction in progress will affect the CHOW timeline and may require remediation as a closing condition.

Litigation and regulatory exposure

The VitalCaring case in Delaware federal court (December 2024) imposed a 43% future-profits decree on VitalCaring (Vistria + Nautic + Anthony Family Investment Partners) running to Encompass/Enhabit, plus $43.1M attorney fees and damages collected in February 2026. The lesson for buyers: founder non-compete and trade-secret diligence is not optional. Verify executive non-competes, confirm no pending or threatened litigation tied to physician relationships, employee misappropriation, or hospice referral practices.

CMS 855A CHOW and the cash flow gap

The single biggest mechanical difference between buying a home health business and buying any other home services company is the CMS 855A Change of Ownership timeline. Get this wrong and the deal’s cash flow assumptions blow up in the first 90 days post-close.

The CHOW timeline reality

A 855A CHOW (the application required to transfer a Medicare-certified home health agency or hospice to new ownership) takes 4–12 months from submission to approval. During the lag, the agency continues to bill under the seller’s legacy PTAN, but the new owner has limited ability to make material changes that would trigger a re-survey. State license CHOW timelines layer on top: in non-CON states, 60–120 days; in CON states, 90–180 days with the possibility of public comment periods.

Structuring around CHOW lag

Sophisticated buyers structure the transaction with explicit CHOW provisions. The standard architecture: equity-style transaction (membership interest purchase, not asset purchase) to preserve the PTAN and avoid triggering a new survey; transition services agreement with the seller covering the CHOW lag period; receivables true-up at the CHOW approval date; and a portion of purchase price held in escrow until CHOW completion. Asset-deal structures (which trigger a new initial survey) are rarely advisable in home health and hospice because the timeline can stretch to 12–18 months and the agency is effectively unsold during the lag.

The Medicare receivables ramp

For asset deals or new-PTAN transactions, the seller’s receivables are excluded and the buyer’s receivables build from $0 over the first 60–90 days. Plan for negative cash flow during the ramp and underwrite the working capital line accordingly. For membership-interest transactions, receivables transfer with the entity and the cash flow ramp is much shorter (often 15–30 days), which is the primary reason buyers prefer equity structures even at a small purchase-price premium.

EVV vendor lock-in and system risk

EVV is the operational lock that most first-time buyers underestimate. The 21st Century Cures Act requires Electronic Visit Verification for Medicaid personal care (2020) and home health (2023). States chose vendor architectures (open vendor, state-mandated aggregator, or single-vendor model) that affect the agency’s switching cost.

Three vendors dominate: HHAeXchange (strongest in NY, NJ, and Northeast), Sandata (state aggregator in many southern states), and Tellus. The diligence question is not just “what vendor are they on” but: what is the remaining contract term, what are the assignment terms under a CHOW, what is the integration depth with the agency’s billing system, and what is the actual capture rate (industry median is 92–95%; below 90% signals operational or training problems that will create Medicaid claim denials).

Buyers who plan to consolidate multiple acquisitions onto a single EVV platform should price the migration cost (typically $50–$150 per caregiver in implementation, plus 60–120 days of dual-platform operation) into the underwriting.

Certificate of Need states and MLTSS payor mix

Two state-level structural factors materially affect what a home health business is worth and who can buy it.

CON states

Seventeen states require a Certificate of Need to open a new home health agency: NC, GA, AL, MS, KY, WV, AR, IL, MI, NJ, NY, OH, PA, SC, TN, VA, WA. In these markets, the existing license is a moat that buyers pay a premium to acquire. Conversely, growing organically in a CON state requires a 12–24 month CON application process with no guarantee of approval, which is why platform buyers preferentially acquire in CON states rather than build de novo.

MLTSS payor mix

Managed Long-Term Services and Supports programs are reshaping the Medicaid payor side of home care. Major MLTSS structures by state: Pennsylvania CHC, New Jersey, Virginia CCC Plus, Tennessee CHOICES, Arizona ALTCS (single-MCO model), Wisconsin Family Care, Texas STAR+PLUS (September 2024 reprocurement), and Oklahoma SoonerSelect (2024–2026 rollout). Each MLTSS rate structure produces different effective rates per hour, different prior-authorization friction, and different EVV requirements. Buyers should pull the agency’s payor mix by line of business and rebuild the trailing 12-month revenue model under the current rate sheet, not just the historical realized rate.

Structuring the offer

The best home health buyers win on structure as often as on price. A well-structured offer can beat a higher nominal offer if it matches what the seller actually cares about: CHOW continuity, caregiver retention, payor relationship preservation, and personal liability exposure.

The standard home health deal structure (2026)

• Cash at close: 65–75% of total consideration. Equity-style transaction with PTAN preserved.
• Seller rollover equity: 10–20% in platform deals where the seller remains operationally engaged. Hospice rollovers often run higher because the founder’s clinical leadership is core to referral retention.
• Earnout: 10–15% over 12–24 months, tied to HHVBP performance, caregiver retention, or referral source retention. EBITDA-based earnouts are rare in home health because reimbursement changes can confound the math.
• Escrow: 10–15% held 18–24 months against indemnification, with a portion released at CHOW approval and the remainder at the survey window.
• Seller note: 0–10%, often used to bridge the CHOW lag period rather than long-term financing.

Where smart buyers differentiate

The offer components home health sellers weight most heavily (in order): cash at close percentage, CHOW execution plan, caregiver and clinical leader retention commitments, payor relationship preservation, and timeline certainty. Founders in this space have often spent 15–30 years building physician and hospital referral relationships; they care about whether those relationships survive the transaction.

Buyers who win on non-price factors typically: pre-commit to clinical leader retention bonuses (often 6–12 months salary for the DON, medical director, and key branch managers), write earnouts with HHVBP-tied floors (top-quartile performance triggers a minimum payment), provide reps and warranties insurance to reduce seller escrow exposure, and bring a detailed CHOW plan to the LOI conversation that demonstrates the buyer has done this before.

Financing a home health acquisition

Capital structure varies by buyer type, but home health has some category-specific patterns.

Senior debt

Commercial banks and unitranche lenders with healthcare expertise will lend 3.5–5.0x EBITDA for Medicare-certified home health and hospice platforms with documented compliance, top-quartile HHVBP, and balanced payor mix. Rates run prime plus 2.0–3.5% with cash flow covenants. Capital One Healthcare, BMO Healthcare, Truist, and Webster Bank are active in the category. For non-medical home care, lenders are more cautious because the EVV-driven Medicaid receivables can be slower to collect.

Mezzanine and unitranche

For platform deals ($10M+ EBITDA), mezzanine or unitranche bridges senior debt and equity. Rates run 10–14% with warrants. Twin Brook Capital Partners, Monroe Capital, Antares Capital, NXT Capital, and Audax Mezzanine are active providers. For hospice platforms with strong per-diem economics, total debt can reach 5.5–6.5x including the mezz tranche.

SBA 7(a) for non-medical home care

Independent buyers acquiring non-medical home care franchise units or sub-$5M EBITDA agencies commonly use SBA 7(a). Rates are prime plus 2.0–2.75% with 10-year amortization. SBA does not finance Medicare-certified home health or hospice acquisitions where the CHOW timeline creates a sustained period of seller billing.

Seller financing

Often 5–15% of purchase price, subordinated, 5–7 year term. Particularly valuable in home health because it can bridge the CHOW lag and align seller interests with smooth payor and referral source transition.

Integration: where acquirers create or destroy value

PE platforms cite their integration playbooks publicly, but the reality varies. The home health deals that compound are the ones where buyers respect three principles.

Do not touch clinical workflows in the first 90 days

OASIS coding, clinical pathway adherence, and HHVBP score-driving behaviors are the result of years of training and culture. Buyers who impose new EMR templates, new clinical pathways, or new productivity standards in month one frequently see HHVBP scores degrade by year-end. The correct approach is a 12–18 month clinical optimization program with the existing DON leading the change rather than corporate overlay.

Protect the caregiver workforce immediately

Top home health and hospice clinicians know their worth and have options. Once a transaction is announced, competing agencies recruit aggressively within 48 hours. Smart buyers structure retention bonuses for named clinicians (typically 10–25% of annual compensation paid over 12–24 months), pre-commit to wage and benefit parity through the integration period, and announce the deal to staff with a clear retention narrative before the rumor mill starts.

Preserve the referral relationships

Home health, home care, and hospice revenue runs through hospital discharge planners, physician practices, hospitalist groups, and ALF directors. These relationships are built over years and can disappear in weeks if the integration is clumsy. Buyers who keep the existing community relations team intact, brief referral sources personally within the first 30 days, and avoid any change to clinical access or response time during the transition typically preserve the revenue base.

Red flags that kill home health deals

Some home health deals should not close. The patterns that consistently predict post-close failure:

• Quality of earnings reveals greater than 20% EBITDA adjustment. Usually from owner compensation normalization, non-recurring COVID-era PHE adjustments, aggressive bad-debt accounting, or unallowable related-party transactions. A 10–15% adjustment is normal; above 20% the diligence premium typically renders the deal uneconomic.
• Hospice running at or over cap. If trailing 36-month per-beneficiary cap utilization exceeds 95%, future recoupment is a near-certain liability. The remediation typically requires admissions discipline that compresses revenue.
• HHVBP bottom quartile. A bottom-quartile HHVBP score means a sustained 5% payment reduction. Without a credible 18–24 month remediation plan, the multiple should reflect at least 1.5x EBITDA discount.
• Single referral source above 30%. Concentration risk plus Stark/AKS exposure. The remediation timeline is long and the litigation tail is real.
• Survey deficiencies unresolved. Condition-level deficiencies or immediate jeopardy findings in the trailing 12 months create a CHOW survey delay that can stretch the timeline by 6+ months.
• Caregiver turnover above 50% in home health, 75% in non-medical home care. Signals a compensation, scheduling, or management problem that takes 18–36 months to fix.
• EVV compliance below 88%. Indicates either operational discipline issues or a vendor implementation that has never stabilized. Either way the Medicaid claim denial rate will be elevated.

The CT Acquisitions perspective

We work both sides of the home health market: introducing sellers to qualified buyers and sourcing deal flow for institutional buyer networks that have engaged us. Our observations from the last 36 months of home health, home care, and hospice M&A:

• Sub-vertical matters more than size. Buyers who underwrite home health, home care, and hospice with the same model consistently mispriced one of the three. The clinical economics, payor mix, and regulatory exposure are different enough that a multi-line target requires three separate diligence streams.
• CHOW execution is a buyer skill, not a checkbox. The buyers who close on time are the ones who pre-mapped the 855A submission, the state license CHOW filing, the EVV reassignment, the payor recredentialing, and the survey logistics before LOI. The buyers who treat CHOW as the regulatory consultant’s problem routinely add 4–8 months to close.
• Hospice is the highest-conviction sub-vertical for 2026. With VBID hospice carve-in ending December 31 2025 and FFS Medicare resuming January 1 2026, the per-diem economics are clean, the demographics are inelastic, and the multiple band (12–15x for platform) reflects sustained competitive bidding. Bristol Hospice is the public anchor; Three Oaks Hospice (Martis Capital since approximately October 2024 for $150M, not Cressey & Co.) and Compassus are the comparable platform cases.
• Watch the buyer roster carefully. BAYADA is nonprofit (not for sale). Honor is Andreessen Horowitz, Baillie Gifford, and T. Rowe Price (not KKR). Comfort Keepers is Halifax (not Sodexo, which divested in September 2023). Three Oaks Hospice is Martis Capital (not Cressey). Gentiva is CD&R 60% and Humana 40% (with Curo Health Services fully absorbed). VitalCaring carries the 43% future-profits decree to Encompass/Enhabit. Misreading the buyer roster wastes weeks.

If you’re a buyer, here’s what we recommend

Whether you are a first-time search fund buyer, an independent sponsor building a healthcare thesis, or a PE platform looking for add-ons, the same playbook works in home health:

1. Write down which sub-vertical you are actually buying. Medicare-certified home health, non-medical home care, and hospice require different operating teams, different diligence specialists, and different capital structures. Mixed-line acquisitions need a clear primary thesis.
2. Build the CHOW playbook before you bid. Identify the 855A consultant, the state license counsel, the EVV transition vendor, the payor recredentialing partner, and the survey readiness team. Bring this team to LOI conversations. Sellers notice the difference.
3. Underwrite payor mix to current rate sheets, not history. HHVBP, the VBID sunset, MLTSS reprocurement, and state minimum wage changes are all moving fast enough that trailing-twelve revenue is not the right baseline.
4. Lead with caregiver and clinical leader retention. The financial deal does not work if the DON leaves in month two and 30% of caregivers follow. Retention commitments, communication discipline, and pay/benefit continuity are what separate the winners from the losers.
5. Do not overpay for a CON moat you cannot operate. A CON state license is valuable only if the buyer can execute the clinical model in that state. CON without clinical leadership in market is paying for an option you cannot exercise.

Working with CT Acquisitions as a buyer

We maintain a qualified buyer network of healthcare PE platforms, strategic acquirers (including direct mandates with two of the largest home health and hospice consolidators), family offices, independent sponsors, and search funds. If your thesis fits the deal flow we see in home health, home care, or hospice, we are direct, fast, and selective about the introductions we make. We do not run broad auction processes. We match founders to the small number of buyers who are right for their specific business, sub-vertical, payor mix, and state footprint.

For buyers, this means: no wasted time on mis-fit deals, early access to deals that have not gone to market, and a sellers-first reputation that founders trust in a category where reputation moves quickly. We are paid by the buyer at close. Founders pay nothing.

If you are actively acquiring in home health, home care, or hospice, set up a 30-minute conversation to walk us through your thesis. We will be direct about whether our deal flow fits.

Frequently asked questions about buying a home health business

What EBITDA multiple should I pay for a home health business in 2026?

It depends on which sub-vertical. Medicare-certified home health platforms transact at 8x–12x EBITDA, anchored by the Enhabit go-private to Kinderhook Industries in May 2026 at 10.2x on $108M EBITDA. Non-medical home care platforms transact at 7x–11x, with TEAM Services/General Atlantic at $3B in April 2026 setting the ceiling at roughly 10x. Hospice platforms transact at 9x–15x or higher, with Bristol Hospice (Webster Equity) reportedly attracting $1B+ sponsor bids on $140M EBITDA in March 2026.

How long does it take to close a home health acquisition?

From signed LOI to economic close, 90–150 days is typical. The CMS 855A CHOW approval takes another 4–12 months after that, which is why most transactions use equity-style structures that preserve the seller PTAN through the CHOW lag. In CON states, the state license CHOW adds 60–180 days. Sophisticated buyers with dedicated regulatory teams close faster.

Should I use an SBA loan to buy a home health business?

SBA 7(a) works for non-medical home care acquisitions up to roughly $5M in purchase price and franchise unit acquisitions. SBA does not finance Medicare-certified home health or hospice acquisitions where the CHOW timeline creates a sustained gap between seller billing and buyer revenue recognition. For Medicare-certified deals, commercial bank or unitranche financing is the standard path.

What is the biggest mistake first-time home health buyers make?

Underestimating the CMS 855A CHOW timeline and the clinical leader retention dynamic. The CHOW lag (4–12 months) is mechanical and predictable but it requires equity-deal structuring and explicit working capital planning. Clinical leader retention (DON, medical director, branch managers) is the difference between preserving and destroying the revenue base. First-time buyers often focus on the financial deal and miss both.

Can I buy a home health business with no healthcare experience?

For non-medical home care, yes, with a strong administrator in place and a 12–24 month founder transition. For Medicare-certified home health and hospice, it is significantly harder because the regulatory complexity (PDGM, HHVBP, hospice cap, HOPE, OASIS-E, CON, EVV, Stark, AKS) is not something a non-healthcare buyer can absorb on the fly. The cleanest path is partnering with a sponsor or operator who has run a similar agency.

How does the CMS 855A CHOW affect the deal structure?

The CHOW timeline (4–12 months) drives buyers toward equity-style transactions (membership interest purchase) that preserve the seller’s PTAN and avoid triggering a new initial survey. Asset deals trigger a new PTAN and a new survey, which can stretch the timeline to 12–18 months and effectively leave the agency unsold during the lag. Most home health and hospice deals are structured as equity transactions for this reason.

What is HHVBP and how does it affect valuation?

The Home Health Value-Based Purchasing model went nationwide January 1 2025 and applies +/-5% payment adjustments based on Care Compare quality measures. A top-quartile agency receives +5% and a bottom-quartile agency loses 5%. The 10-point spread is a direct margin driver and translates to roughly 0.5–1.5x EBITDA multiple difference in valuation. Buyers diligence HHVBP performance as a primary multiple input.

What happened with the VBID hospice carve-in?

The Value-Based Insurance Design hospice carve-in pilot ended December 31 2024, and the broader VBID model ended December 31 2025. Hospice care reverts to traditional Medicare fee-for-service billing from January 1 2026. The change simplifies the payor model and removes a source of MA-plan negotiating power, which is part of why hospice multiples have firmed up in 2026.

Related resources for buyers

• Home health valuations and multiples (seller perspective) — useful context on what sellers are being told
• Home health business valuation guide — PDGM, HHVBP, and hospice cap mechanics
• Buy a business: cross-vertical playbook — sourcing and underwriting framework
• PE platforms by sector 2026 — complete healthcare consolidator roster
• How to sell a service business — seller-side playbook (useful context for buyer conversations)